member mufg global financi group
solid start year despit larg cancel
report anoth quarter solid oper momentum
midpoint revenu adj ebitda adj ep come
consensu despit set back cancel larg trial net
new busi growth remain robust ttm basi ex pass-
through manag forecast double-digit increas
rfp valu year modestli rais estim
increas price target reflect
multipl adjust ep estim despit
posit quarter solid growth prospect reaffirm neutral
rate believ stock fairli valu current level look
forward better understand manag long-term strategi
technolog capabl upcom investor day schedul
june new york
result report adjust ep yoy
meet top-end manag guidanc rang
our/consensu estim versu model
out-performance evenli split above-the-lin
benefit below-the-lin benefit item
acceler organ revenu growth total revenu
yoy fx adjust modestli exceed top-end
guidanc beat our/consensu estim
estim total organ revenu growth deceler
qoq
continu acceler report growth qoq
constant fx basi qoq
deceler growth due headwind associ
lower pass-through higher proport project start-up
phase report ds revenu growth vs
constant fx growth vs contract
improv revenu declin vs
declin fx adjust vs
total repres qoq growth
qoq expect convert revenu next
twelv month backlog adjust recent clinic trial
revenu still repres yoy growth ttm net
share
import disclosur analyst certif begin page
book-to-bil strong ahead
ebitda ahead consensu adj ebitda yoy
near high-end guidanc exceed
our/consensu estim out-performance
attribut oper execut adj ebitda margin
increas qoq yoy
flow debt capit deploy neg
advers impact employe incent payment
time receipt disburs net debt adjust ebitda
increas qoq repurchas stock
quarter author remain end
scale capabl includ ai support single-arm trial
studi countri leverag ai
machin learn cloud-bas orchestr custom engag
oce sale team engag activ sale lead
cro side gross new busi clinic trial award support next-gen
technolog total compani smart trial
oper repres one-third total trial
guidanc element includ revenu rang
adjust ebitda rang
adjust ep guidanc introduc total
revenu adjust ebitda
adjust ep
estim chang adjust model reflect
out-performance introduct guidanc adjust
ep estim increas yoy
adjust ep estim yoy
estim yoy
valuat current trade premium peer group
price-to-earnings basi per share target base
multipl adjust ep estim
dollar million except ep compani report musa
incom yoy yoy growth constant fx ebitda yoy integr revenu purchas acct adj ebitda yoy adj ebitda margin constant oper oper debt incom unconsolid attribut pre-tax adjust tax adjust tax incom minor interest effect ni yoy average share yoy us equiti research
believ iqvia benefit industri tailwind around bio-
pharmaceut spend clinic trial outsourc compani
invest real-world insight next-gen cro offer may
translat competit advantag contribut acceler top-lin
growth opportun howev may take time servic offer
evolv contribut revenu earn growth
current trade premium peer group price-to-earnings
view per share target base multipl
risk recommend downsid upsid includ
acceler slowdown bio-pharmaceut research
develop gain loss contract chang healthcar
regulatori environ chang reimburs level chang
competit landscap
iqvia world largest clinic research organ cro provid
biopharmaceut client outsourc research develop
product commerci form merger quintil
im health octob iqvia one largest
comprehens collect world-wide healthcar inform
compani expect gener revenu
carri contract backlog excess
